Adult Cigarette Smoking Declined Between 1993 and 2000: CDC Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

WASHINGTON- The Centers for Disease Control and Prevention (CDC) reported a modest but statistically significant decrease in the number of US cigarette smokers. The new analysis involved self-reported data generated by the 2000 National Interview Survey sample adult core questionnaire and cancer control module. The report found that about 23.3% of adults are current smokers vs 25.0% in 1993. Seventy percent of adult smokers said they wanted to quit, and 41% had tried to quite at least once.

WASHINGTON—The Centers for Disease Control and Prevention (CDC) reported a modest butstatistically significant decrease in the number of US cigarette smokers. Thenew analysis involved self-reported data generated by the 2000 NationalInterview Survey sample adult core questionnaire and cancer control module. Thereport found that about 23.3% of adults are current smokers vs 25.0% in 1993.Seventy percent of adult smokers said they wanted to quit, and 41% had tried toquite at least once.

Articles in this issue
Tumor-Specific Idiotype Vaccines Promising in B-Cell Lymphomas
Childhood Survivors May Not Know Their Past Rx
Pemetrexed/Gemcitabine Promising in Advanced Pancreatic Cancer
Physician Experience Predicts HIV-Related Mortality
Preliminary Phase III Results for Provenge Vaccine in Prostate Cancer
Eloxatin With 5-FU/LV Approved for Recurrent Colon Cancer
Comprehensive Geriatric Evaluations Improve Care
Nordion’s Monte Carlo Dose Calculation Software Approved
No Strong Link Between Breast Cancer Risk and Pollutants
Imatinib Inactive in Sarcomas That Lack C-KIT/PDGF
Task Force Recommends Screening for All Age 50 and Over
No Link Between Breast Cancer Risk and Pollutants
NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials
Medicare Puts PET for Thyroid Cancer, Soft Tissue Sarcoma on Hold
Cranial Radiotherapy for Childhood ALL Linked to Adult Obesity
Recent Videos
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Related Content
Explore how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

Aliasgar Shahiwala, PhD
October 25th 2025
Article

Explore how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC

Roman Fabbricatore
October 24th 2025
Article

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma

Ariana Pelosci
October 24th 2025
Article

For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.

Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.